{"id":"asp8232","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, ASP8232 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.","oneSentence":"ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:28.830Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT02358096","phase":"PHASE2","title":"A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-03-17","conditions":"Chronic Kidney Disease, Type 2 Diabetes","enrollment":125},{"nctId":"NCT02302079","phase":"PHASE2","title":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-12","conditions":"Diabetes Mellitus, Diabetic Macular Edema","enrollment":96},{"nctId":"NCT02218099","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09-16","conditions":"Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASP8232","genericName":"ASP8232","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Treatment of autoimmune diseases.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}